Javelin Oncology announced today that the company has hired Steven Yecies as Chief Executive Officer. Yecies brings 30 years of experience as an accomplished senior executive, consultant, and investor in the healthcare and life sciences industry.
Virtici ASCEND participant company, Inimmune, raises $22 Million in Series A Funding Led by Two Bear Capital
Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding.
Celdara Medical, LLC today announced that the first DRIVEN Accelerator Hub Participant Company, CairnSurgical, Inc., has closed a Series A investment led by Morningside Group.
Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company with headquarters in South Korea. The deal gives Genome & Co a majority stake in Scioto and expands its presence into the US.
Rise Therapeutics Secures Funding to Develop a Novel Immunologically-Directed Probiotic for the Treatment of Inflammatory Bowel Disease
Rise Therapeutics, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) grant to fund the development of the novel engineered probiotic for the treatment of inflammatory bowel disease (IBD).
Virtici, LLC announced today the award of supplemental funds to the ASCEND Accelerator Hub. The ASCEND Accelerator Hub is an NIH-funded consortium led by Virtici and includes 10 of the leading research institutions in the Western States (Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming).